Corporate Profile

Inotiv, Inc., provides drug discovery and development services and analytical instruments that help pharmaceutical, biotechnology, leading academic institutions and government organizations in their drug development and research efforts. Our mission is to provide drug developers with superior scientific research and innovative analytical instrumentation, which saves time, saves money, and saves lives, to bring revolutionary new drugs to market quickly and safely. Our strategy is to provide services that will generate high-quality and timely data in support of new drug approval or use expansion. To learn more about our portfolio of services, click here.

Investor News

  • Click here to listen to the audio recording of the BASi/Inotiv 2021 Annual Meeting of Shareholders held on Thursday, March 18, 2021.
  • Click here to listen to the March 9-10, 2021, webcast of BASi/Inotiv’s presentation at the H.C. Wainwright Global Life Sciences Virtual Conference. Click here to view the presentation deck.
  • Click here for the recording of our Q1 FY 2021 Financial Results Conference Call held on Tuesday, February 9, 2021, at 4:30pm ET.
  • Click here to listen to the September 16, 2020, recording of BASi/Inotiv’s presentation at the H.C. Wainwright 22nd Annual Global Investment Conference. Click here to view the presentation deck.

SEC Filings | Section 16 Filings

Inotiv, Inc. Releases Earnings for First Quarter of Fiscal 2021

Tuesday, February 9, 2021​

Results

Investor Relations
Beth A. Taylor, Chief Financial Officer
Inotiv, Inc.
765.497.8381
Email

Kalle Ahl, CFA
The Equity Group
212.836.9614
Email

Devin Sullivan
The Equity Group
212.836.9608
Email